COVID-19 convalescent plasma safety and efficacy analysis for biologics license application approval

20260 citationsJournal Articlegreen Open Access

Authors

David J. Sullivan · Johns Hopkins University

Rita Reik · OneBlood

Alicia Prichard · OneBlood

Marlene Pagan · OneBlood

Aaron A. R. Tobian · Johns Hopkins University

Patrizio Caturegli · Johns Hopkins University

Andrew Pekosz · Johns Hopkins University

Abstract

With pandemic progression, the COVID-19 convalescent plasma safety and efficacy evidence quality increased. Ultimate regulatory approval required robust randomized control efficacy data. Future infectious disease outbreaks require randomized controlled trials in the convalescent plasma roadmap.

Topics & Keywords

SARS-CoV-2 and COVID-19 Research COVID-19 Clinical Research Studies SARS-CoV-2 detection and testing

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Expert Review of Anti-infective Therapy

Volume 24, Issue 1, pp. 97-111

DOI: 10.1080/14787210.2026.2623136

Field-Weighted Citation Impact: 0.00